REFERENCIAS
1. Vakil N, Stelwagon M, Shea EP, Miller S. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J 2016;4:431-22.
2. Enck P, Leinert J, Smid M, Kohler T, Schwille-Kiuntke J. Somatic comorbidity in chronic constipation: more data from the GECCO study. Gastroenterol Res Pract 2016;2016:5939238.
3. Drossman DA. Functional Gastrointestinal Disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;Feb 1. pii: S0016- 5085(16)00223-7.
4. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1:133-46.
5. Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol. 2014;20:8898-909.
6. Mearin F, Ciriza C, Minguez M, Rey E4, Mascort JJ5, Peña E, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108:32-63.
7. Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL. Cisapride for intestinal constipation. Cochrane Database Syst Rev. 2011;(1):CD007780.
8. Ryu HS, Choi SC. Recent updates on the treatment of constipation. Intest Res. 2015;13:297-305.
9. Love BL, Johnson A, Smith LS. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014;71:1081-91.
10. Jin Y, Blikslager AT. ClC-2 regulation of intestinal barrier function: translation of basic science to therapeutic target. Tissue Barriers. 2015;3(4):e1105906.
11. Thomas RH, Luthin DR. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Pharmacotherapy. 2015;35:613-30.
12. Schoenfeld P, Cook D, Hamilton F, Laine L, Morgan D, Peterson W. An evidence-based approach to gastroenterology therapy. Gastroenterology. 1998;114:1318-25.
13. Johnston JM, Kurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877-86.
14. Lembo AJ, Kurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886-95.
15. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527-36.
16. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702-12.
17. Rao SS, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714-24.
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.